Induction of P-glycoprotein by antiretroviral drugs in human brain microvessel endothelial cells

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 9, 2013, Pages 4481-4488

  Chan, Gary N Y ^a   Patel, Rucha ^a   Cummins, Carolyn L ^a   Bendayan, Reina ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; CONSTITUTIVE ANDROSTANE RECEPTOR; DARUNAVIR; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; LOPINAVIR; MARAVIROC; MULTIDRUG RESISTANCE PROTEIN; NEVIRAPINE; PREGNANE X RECEPTOR; RALTEGRAVIR; RIFAMPICIN; RITONAVIR; TENOFOVIR; ZIDOVUDINE;

ANIMAL CELL; ARTICLE; BLOOD BRAIN BARRIER; BRAIN BLOOD VESSEL; DRUG PROTEIN BINDING; FIBROBLAST; HUMAN; HUMAN TISSUE; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; VASCULAR ENDOTHELIUM;

ANTIVIRAL AGENTS; BRAIN; CELL LINE; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; GENE EXPRESSION REGULATION; GENES, REPORTER; HUMANS; LUCIFERASES; MICROVESSELS; P-GLYCOPROTEIN; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, STEROID; SIGNAL TRANSDUCTION;

EID: 84882411179     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00486-13     Document Type: Article

References (50)

1. Letendre S. 2011. Central nervous system complications in HIV disease: HIV-associated neurocognitive disorder. Top. Antivir. Med. 19:137-142.
2. Vivithanaporn P, Heo G, Gamble J, Krentz HB, Hoke A, Gill MJ, Power C. 2010. Neurologic disease burden in treated HIV/AIDS predicts survival: a population-based study. Neurology 75:1150-1158.
3. Cysique LA, Brew BJ. 2009. Neuropsychological functioning and antiretroviral treatment in HIV/AIDS: a review. Neuropsychol. Rev. 19:169-185.
4. Ene L, Duiculescu D, Ruta SM. 2011. How much do antiretroviral drugs penetrate into the central nervous system? J. Med. Life 4:432-439.
5. Löscher W, Potschka H. 2005. Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog. Neurobiol. 76:22-76.
6. Tsuji A, Terasaki T, Takabatake Y, Tenda Y, Tamai I, Yamashima T, Moritani S, Tsuruo T, Yamashita J. 1992. P-glycoprotein as the drug efflux pump in primary cultured bovine brain capillary endothelial cells. Life Sci. 51:1427-1437.
7. Schinkel AH, Wagenaar E, Mol CA, van Deemter L. 1996. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J. Clin. Invest. 97:2517-2524.
8. Lee CA, Cook JA, Reyner EL, Smith DA. 2010. P-glycoprotein related drug interactions: clinical importance and a consideration of disease states. Expert Opin. Drug Metab. Toxicol. 6:603-619.
9. Kis O, Robillard K, Chan GNY, Bendayan R. 2010. The complexities of antiretroviral drug-drug interactions: role of ABC and SLC transporters. Trends Pharmacol. Sci. 31:22-35.
10. Perloff MD, von Moltke LL, Greenblatt DJ. 2004. Ritonavir and dexamethasone induce expression of CYP3A and P-glycoprotein in rats. Xenobiotica 34:133-150.
11. Perloff MD, von Moltke LL, Fahey JM, Greenblatt DJ. 2007. Induction of P-glycoprotein expression and activity by ritonavir in bovine brain microvessel endothelial cells. J. Pharm. Pharmacol. 59:947-953.
12. Zastre JA, Chan GNY, Ronaldson PT, Ramaswamy M, Couraud PO, Romero IA, Weksler B, Bendayan M, Bendayan R. 2009. Up-regulation of P-glycoprotein by HIV protease inhibitors in a human brain microvessel endothelial cell line. J. Neurosci. Res. 87:1023-1036.
13. Urquhart BL, Tirona RG, Kim RB. 2007. Nuclear receptors and the regulation of drug-metabolizing enzymes and drug transporters: implications for interindividual variability in response to drugs. J. Clin. Pharmacol. 47:566-578.
14. Bauer B, Hartz AMS, Fricker G, Miller DS. 2004. Pregnane X receptor up-regulation of P-glycoprotein expression and transport function at the blood-brain barrier. Mol. Pharmacol. 66:413-419.
15. Bauer B, Yang X, Hartz AMS, Olson ER, Zhao R, Kalvass JC, Pollack GM, Miller DS. 2006. In vivo activation of human pregnane X receptor tightens the blood-brain barrier to methadone through P-glycoprotein up-regulation. Mol. Pharmacol. 70:1212-1219.
16. Ott M, Fricker G, Bauer B. 2009. Pregnane X receptor (PXR) regulates P-glycoprotein at the blood-brain barrier: functional similarities between pig and human PXR. J. Pharmacol. Exp. Ther. 329:141-149.
17. Wang X, Sykes DB, Miller DS. 2010. Constitutive androstane receptormediated up-regulation of ATP-driven xenobiotic efflux transporters at the blood-brain barrier. Mol. Pharmacol. 78:376-383.
18. Lemmen J, Tozakidis IEP, Bele P, Galla HJ. 2013. Constitutive androstane receptor upregulates Abcb1 and Abcg2 at the blood-brain barrier after CITCO activation. Brain Res. 1501:68-80.
19. Chan GN, Hoque MT, Cummins CL, Bendayan R. 2011. Regulation of P-glycoprotein by orphan nuclear receptors in human brain microvessel endothelial cells. J. Neurochem. 118:163-175.
20. Chang TKH, Waxman DJ. 2006. Synthetic drugs and natural products as modulators of constitutive androstane receptor (CAR) and pregnane X receptor (PXR). Drug Metab. Rev. 38:51-73.
21. Dussault I, Lin M, Hollister K, Wang EH, Synold TW, Forman BM. 2001. Peptide mimetic HIV protease inhibitors are ligands for the orphan receptor SXR. J. Biol. Chem. 276:33309-33312.
22. Svärd J, Spiers JP, Mulcahy F, Hennessy M. 2010. Nuclear receptormediated induction of CYP450 by antiretrovirals: functional consequences of NR1I2 (PXR) polymorphisms and differential prevalence in whites and sub-Saharan Africans. J. Acquir. Immune Defic. Syndr. 55: 536-549.
23. Hariparsad N, Nallani SC, Sane RS, Buckley DJ, Buckley AR, Desai PB. 2004. Induction of CYP3A4 by efavirenz in primary human hepatocytes: comparison with rifampin and phenobarbital. J. Clin. Pharmacol. 44: 1273-1281.
24. Gupta A, Mugundu GM, Desai PB, Thummel KE, Unadkat JD. 2008. Intestinal human colon adenocarcinoma cell line LS180 is an excellent model to study pregnane X receptor, but not constitutive androstane receptor, mediated CYP3A4 and multidrug resistance transporter 1 induction: studies with anti-human immunodeficiency virus protease inhibitors. Drug Metab. Dispos 36:1172-1180.
25. Weksler BB, Subileau EA, Perrière N, Charneau P, Holloway K, Leveque M, Tricoire-Leignel H, Nicotra A, Bourdoulous S, Turowski P, Male DK, Roux F, Greenwood J, Romero IA, Couraud PO. 2005. Blood-brain barrier-specific properties of a human adult brain endothelial cell line. FASEB J. 19:1872-1874.
26. Patel R, Patel M, Tsai R, Lin V, Bookout AL, Zhang Y, Magomedova L, Li T, Chan JF, Budd C, Mangelsdorf DJ, Cummins CL. 2011. LXR is required for glucocorticoid-induced hyperglycemia and hepatosteatosis in mice. J. Clin. Invest. 121:431-441.
27. Capparelli EV, Holland D, Okamoto C, Gragg B, Durelle J, Marquie-Beck J, Van Den Brande G, Ellis R, Letendre S. 2005. Lopinavir concentrations in cerebrospinal fluid exceed the 50% inhibitory concentration for HIV. AIDS 19:949-952.
28. Croteau D, Letendre S, Best BM, Rossi SS, Ellis RJ, Clifford DB, Collier AC, Gelman BB, Marra CM, McArthur J, McCutchan JA, Morgello S, Simpson DM, Way L, Capparelli E, Grant I. 2012. Therapeutic amprenavir concentrations in cerebrospinal fluid. Antimicrob. Agents Chemother. 56:1985-1989.
29. Yilmaz A, Izadkhashti A, Price RW, Mallon PW, De Meulder M, Timmerman P, Gisslén M. 2009. Darunavir concentrations in cerebrospinal fluid and blood in HIV-1-infected individuals. AIDS Res. Hum. Retroviruses 25:457-461.
30. Tashima KT, Caliendo AM, Ahmad M, Gormley JM, Fiske WD, Brennan JM, Flanigan TP. 1999. Cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) suppression and efavirenz drug concentrations in HIV-1-infected patients receiving combination therapy. J. Infect. Dis. 180:862-864.
31. McDowell JA, Chittick GE, Ravitch JR, Polk RE, Kerkering TM, Stein DS. 1999. Pharmacokinetics of [14C]abacavir, a human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitor, administered in a single oral dose to HIV-1-infected adults: a mass balance study. Antimicrob. Agents Chemother. 43:2855-2861.
32. Antinori A, Perno CF, Giancola ML, Forbici F, Ippolito G, Hoetelmans RM, Piscitelli SC. 2005. Efficacy of cerebrospinal fluid (CSF)-penetrating antiretroviral drugs against HIV in the neurological compartment: different patterns of phenotypic resistance in CSF and plasma. Clin. Infect. Dis. 41:1787-1793.
33. Pal D, Kwatra D, Minocha M, Paturi DK, Budda B, Mitra AK. 2011. Efflux transporters-and cytochrome P-450-mediated interactions between drugs of abuse and antiretrovirals. Life Sci. 88:959-971.
34. Pomerantz RJ. 2003. Reservoirs, sanctuaries, and residual disease: the hiding spots of HIV-1. HIV Clin. Trials 4:137-143.
35. Maglich JM, Parks DJ, Moore LB, Collins JL, Goodwin B, Billin AN, Stoltz CA, Kliewer SA, Lambert MH, Willson TM, Moore JT. 2003. Identification of a novel human constitutive androstane receptor (CAR) agonist and its use in the identification of CAR target genes. J. Biol. Chem. 278:17277-17283.
36. Li H, Chen T, Cottrell J, Wang H. 2009. Nuclear translocation of adenoviral-enhanced yellow fluorescent protein-tagged-human constitutive androstane receptor (hCAR): a novel tool for screening hcar activators in human primary hepatocytes. Drug Metab. Dispos. 37:1098-1106.
37. Xue Y, Chao E, Zuercher WJ, Willson TM, Collins JL, Redinbo MR. 2007. Crystal structure of the PXR-T1317 complex provides a scaffold to examine the potential for receptor antagonism. Bioorg. Med. Chem. 15: 2156-2166.
38. Xu RX, Lambert MH, Wisely BB, Warren EN, Weinert EE, Waitt GM, Williams JD, Collins JL, Moore LB, Willson TM, Moore JT. 2004. A structural basis for constitutive activity in the human CAR/RXR heterodimer. Mol. Cell 16:919-928.
39. Khandelwal A, Krasowski MD, Reschly EJ, Sinz MW, Swaan PW, Ekins S. 2008. Machine learning methods and docking for predicting human pregnane X receptor activation. Chem. Res. Toxicol. 21:1457-1467.
40. Perloff ES, Duan SX, Skolnik PR, Greenblatt DJ, von Moltke LL. 2005. Atazanavir: effects on P-glycoprotein transport and CYP3A metabolism in vitro. Drug Metab. Dispos. 33:764-770.
41. Chandler B, Almond L, Ford J, Owen A, Hoggard P, Khoo S, Back D. 2003. The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on P-glycoprotein expression in peripheral blood mononuclear cells in vitro. J. Acquir. Immune Defic. Syndr. 33:551-556.
42. Weiss J, Weis N, Ketabi-Kiyanvash N, Storch CH, Haefeli WE. 2008. Comparison of the induction of P-glycoprotein activity by nucleotide, nucleoside, and non-nucleoside reverse transcriptase inhibitors. Eur. J. Pharmacol. 579:104-109.
43. Dixit V, Hariparsad N, Li F, Desai P, Thummel KE, Unadkat JD. 2007. Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: implications for predicting clinical drug interactions. Drug Metab. Dispos. 35: 1853-1859.
44. Perloff MD, von Moltke LL, Fahey JM, Daily JP, Greenblatt DJ. 2000. Induction of P-glycoprotein expression by HIV protease inhibitors in cell culture. AIDS 14:1287-1289.
45. Vishnuvardhan D, von Moltke LL, Richert C, Greenblatt DJ. 2003. Lopinavir: acute exposure inhibits P-glycoprotein; extended exposure induces P-glycoprotein. AIDS 17:1092-1094.
46. König SK, Herzog M, Theile D, Zembruski N, Haefeli WE, Weiss J. 2010. Impact of drug transporters on cellular resistance towards saquinavir and darunavir. J. Antimicrob. Chemother. 65:2319-2328.
47. Shaik N, Giri N, Pan G, Elmquist WF. 2007. P-glycoprotein-mediated active efflux of the anti-HIV1 nucleoside abacavir limits cellular accumulation and brain distribution. Drug Metab. Dispos. 35:2076-2085.
48. Muzi M, Mankoff DA, Link JM, Shoner S, Collier AC, Sasongko L, Unadkat JD. 2009. Imaging of cyclosporine inhibition of P-glycoprotein activity using 11C-verapamil in the brain: studies of healthy humans. J. Nucl. Med. 50:1267-1275.
49. Bauer M, Zeitlinger M, Karch R, Matzneller P, Stanek J, Jäger Böhmdorfer WM, Wadsak W, Mitterhauser M, Bankstahl JP, Löscher W, Koepp M, Kuntner C, Müller M, Langer O. 2012. Pgp-mediated interaction between (R)-[11C]verapamil and tariquidar at the human bloodbrain barrier: a comparison with rat data. Clin. Pharmacol. Ther. 91:227-233.
50. Syvänen S, Eriksson J. 2013. Advances in PET imaging of P-glycoprotein function at the blood-brain barrier. ACS Chem. Neurosci. 4:225-237.